Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Jeffrey S. Schweitzer, MD, PhD
Study ID
NCT06687837
Phase
PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • autologous dopaminergic cell implantation — BIOLOGICAL
    Dopaminergic progenitor cells derived from autologous induced pluripotent stem cells will be injected into the brain in two cohorts of Parkinson's patients, one receiving low dose and the other high dose (4 and 8 million cells, respectively)

Study Details

The goal of this clinical trial is to assess the safety and tolerability of the surgical transplantation of dopaminergic progenitor cells into the brains of participants with Parkinson's disease. The transplanted dopaminergic cells will be derived from the participant's own skin cells.

Key Dates

Start date
Apr 29, 2025
Status verified
Mar 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
8 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Low dose administration
    4 million autologous dopaminergic cells will be implanted into the putamen on each side of the brain
  • Experimental: High dose administration
    8 million autologous dopaminergic cells will be implanted into the putamen on each side of the brain

Primary Outcome Measure

Safety and Tolerability [ Time Frame: 2 years from time of implantation ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Jeffrey S Schweitzer, MD, PhD
617-726-1799
Dolores Smith
617-726-1799

Find similar trials in Boston, MA

Related Studies